Fortress Biotech shareholders approve director slate, KPMG ratification, and equity plan share increases

Fortress Biotech, Inc.

Elected all 8 directors; Rosenwald received 7.88M for, 279K against; broker non-votes 6.1M.
Ratified KPMG as auditor for FY2024 with 13.93M for, 325K against.
Approved Incentive Plan amendment adding 10M shares and raising annual option/SAR limit to 1M shares.
Approved ESPP amendment adding 1M shares and raising Offering limit to 5,000 shares.
Approved LTIP amendment extending term to July 15, 2035 with related changes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.